



(51) International Patent Classification:
A61K 31/225 (2006.01)

(21) International Application Number:
PCT/US2013/024946

(22) International Filing Date:
6 February 2013 (06.02.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/596,202 7 February 2012 (07.02.2012) US
61/625,621 17 April 2012 (17.04.2012) US
61/723,048 6 November 2012 (06.11.2012) US

(71) Applicant: **BIOGEN IDEC MA INC.** [US/US]; 14 Cambridge Center, Cambridge, MA 02142 (US).

(72) Inventors: **GOLDMAN, David**; 25 Noonhill Road, Medfield, MA 02052 (US). **DAWSON, Katherine**; 561 Canton Street, Westwood, MA 02090 (US). **NIRULA, Ajay**; 2210 Three Springs Drive, Westlake Village, CA 91361 (US).

(74) Agents: **COVERT, John, M.** et al.; Sterne Kessler Goldstein & Fox PLLC, 1100 New York Avenue, N.W., Washington, DC 20005 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE

(57) Abstract: Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w.

